in vivo– tag –
-
Unlocking mRNA LNP Design: Cholesterol Found Unnecessary for Non-Hepatic Delivery
ACS Nano USA Overview New research thoroughly dissects the functional roles of individual lipid components within mRNA lipid nanoparticles (LNPs), revealing that while ionizable lipids are critical for delivery efficacy, cholesterol is e... -
Dual-Targeting Lipid Nanoparticles Drastically Enhance β Cell-Specific RNA Delivery, Promising for Type 1 Diabetes Therapy
ACS Publications USA Overview Researchers have developed a dual-targeting lipid nanoparticle (LNP) engineering strategy that significantly enhances β cell-directed RNA delivery. This novel LNP demonstrated substantially improved in vivo ... -
6th mRNA Therapeutics Summit Highlights Shift to Oncology, with In Vivo CAR-T, saRNA, and circRNA as Key Innovations
BioSpace USA Overview The 6th mRNA-Based Therapeutics Summit revealed a significant shift in mRNA clinical activity from infectious diseases to oncology, with in vivo CAR-T emerging as a notable application. Self-amplifying RNA (saRNA) a... -
LNP-Delivered Gene Editing Platform Targets Hepatic Lipid Metabolic Disorders for Durable, Single-Intervention Correction
Ace Therapeutics USA Overview This platform focuses on lipid nanoparticle (LNP)-delivered gene editing for heritable lipid disorders, aiming for durable, single-intervention correction of disease-driving genes in the liver. It integrates... -
RNA Therapeutics Advance with Delivery Challenges: mRNA Vaccines, siRNAs, and ASOs Drive Disease Treatment
Facebook (Ambry Genetics) USA Overview Recent publications highlight the profound impact of RNA-based therapeutic modalities, including mRNA vaccines, siRNAs, and ASOs, in treating viral infections, genetic disorders, and cancer. However... -
HKeyBio Launches HKEY-AI2Vivo™ 1.0 Program to Accelerate In Vivo Validation for AI-Designed Candidates, Addressing Pre-IND Bottlenecks
Drug Discovery Online USA Overview HKeyBio launched HKEY-AI2Vivo™ 1.0, an AI Candidate In Vivo Validation Acceleration Program, to support AI drug discovery teams in translating AI-generated targets and molecules into in vivo pharmacolog... -
Machine Learning Accelerates Lipid Nanoparticle Design, Streamlining RNA Therapeutic Formulation Development for High Efficacy and Reduced Experimental Burden
Pharmatica USA Overview Machine learning (ML) is being applied to lipid nanoparticle (LNP) design to accelerate formulation development, improve delivery performance, and reduce experimental burden for RNA therapeutics, gene-editing syst... -
ACE Therapeutics’ LNP Gene Editing Platform Achieves Over 90% Hepatocyte Selectivity for Lipoprotein-Targeted Cardiovascular Therapeutics
ACE Therapeutics USA Overview ACE Therapeutics' LNP-delivered gene editing platform achieves over 90% efficient hepatocyte-selective delivery for lipoprotein-targeted cardiovascular therapeutics, minimizing extrahepatic editing risks. Th... -
Backbone-Ionized Polymer iPβAE Quantitatively Guides Extra-Hepatic mRNA Expression to Spleen and Lung
Journal of the American Chemical Society USA Overview A study published in the Journal of the American Chemical Society introduces a backbone-ionized polymer (iPβAE) platform engineered for quantitatively guided extra-hepatic mRNA target... -
Antibiotics Reshape Gut Microbiome, Doubling Circulation Time and Tumor Accumulation of Nano-Chemotherapy, Improving Survival
University of Texas M. D. Anderson Cancer Center USA Overview Researchers at The University of Texas MD Anderson Cancer Center discovered that reshaping the gut microbiome with a short course of antibiotics can enhance the delivery of na...
